Relay Therapeutics Inc. stocks have been trading up by 8.01 percent amid strong optimism over its latest precision oncology advances.
Click Here for a Millionaire's POV on Trading RLAY
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways For RLAY Traders
- Phase 3 trial planned for zovegalisib plus Pfizer’s atirmociclib and fulvestrant in frontline PI3Kα‑mutated HR+/HER2- metastatic breast cancer after strong Phase 1/2 ReDiscover data.
- Early triplet regimen delivered a 44% overall response rate in heavily pretreated HR+/HER2- metastatic breast cancer, hinting at even stronger results in earlier lines.
- Major Wall Street firms — Goldman Sachs, H.C. Wainwright, Oppenheimer, Citizens, and Wells Fargo — all raised RLAY price targets on the back of zovegalisib triplet data.
- Relay Therapeutics posted a wider-than-expected Q1 loss and missed revenue, but spotlighted its breast cancer triplet, vascular anomaly work, and NRAS candidate RLY-8161.
- Pfizer-backed supply deal supports moving the zovegalisib/atirmociclib/endocrine triplet into a frontline Phase 3 trial around early 2027, alongside a separate ongoing second-line Phase 3.
Live Update At 12:35:37 EDT: On Tuesday, May 19, 2026 Relay Therapeutics Inc. stock [NASDAQ: RLAY] is trending up by 8.01%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Relay Therapeutics, trading as RLAY, is acting like a classic clinical-stage biotech: weak earnings today, but a pipeline story driving the chart. The latest quarter showed just $3.0M in revenue against hefty R&D spend of about $70.6M, leading to a net loss of roughly $73.3M, or about -$0.41 per share. Margins are extremely negative and the P/E ratio is not meaningful, which is normal for this kind of name.
What matters for traders is the cash and runway. RLAY ended the quarter with about $205.9M in cash and more than $204.5M in cash and equivalents on the balance sheet, plus over $437M in investments. Current liabilities sit under $30M, and the current ratio is a huge 22.6. Debt is minimal. That tells traders RLAY has room to fund these Phase 3 programs without an emergency raise.
More Breaking News
- GOVX Stock Rockets On Heavy Volume As Traders Pile In
- FLNC Stock Slumps As Secondary Offerings Flood The Market
- EOSE Stock Slides As Lawsuits Mount And Losses Deepen
- OXSQ Stock Slides As Traders Eye Deep Pullback
On the tape, RLAY has been grinding higher from the high $12s to low $13s, closing near $13.06 after bouncing off an intraday low around $11.63. Intraday, the stock washed out off the open, then reclaimed $13 and held it, which short-term momentum traders watch as a sign of dip buying in a catalyst-rich name.
Why Traders Are Watching RLAY Right Now
RLAY is on screens because its story just moved from early proof-of-concept to real late-stage shot-on-goal territory. Relay Therapeutics is pushing its PI3Kα inhibitor zovegalisib into a Phase 3 trial with Pfizer’s CDK4 inhibitor atirmociclib plus endocrine therapy for frontline HR+/HER2- metastatic breast cancer with PI3Kα mutations. That’s a big, targeted segment where success can be transformational for a small-cap biotech.
The fuel behind the excitement is data, not hype. In heavily pretreated patients — a tough crowd to treat — the zovegalisib/atirmociclib/fulvestrant triplet delivered a 44% objective response rate with good tolerability. Analysts have latched onto that. Goldman Sachs raised its RLAY price target to $22 from $13. H.C. Wainwright pushed theirs to $25. Oppenheimer moved to $18, while Citizens and Wells Fargo also bumped targets to the high teens and low $20s, all while keeping positive ratings.
For RLAY traders, that cluster of upgrades matters. It signals the Street sees the Phase 1/2 data as de-risking the upcoming Phase 3 work, not just a small win. Oppenheimer also flagged the absence of Grade 3 hyperglycemia, a key safety concern for the PI3K class. Better tolerability can translate to more real-world use if the drug gets approved.
Relay Therapeutics is not a one-trick pony either. Management highlighted ongoing second-line Phase 3 work, vascular anomaly efforts, and the start of clinical development for NRAS-selective candidate RLY-8161. Add in the Pfizer supply agreement backing the frontline triplet trial expected to start around early 2027, and RLAY suddenly looks like a platform story with multiple ways to win, which momentum traders love to crowd into when charts and news line up.
Conclusion
For active traders, RLAY is a textbook “catalyst versus cash burn” setup. On one side, the company is posting steep losses and negative margins as it spends roughly $70M a quarter on research. On the other, Relay Therapeutics holds more than $200M in cash, low debt, and a beefy working capital position over $600M, buying it time to chase major oncology opportunities with zovegalisib and RLY-8161.
The near-term price action in RLAY reflects that tension. The stock flushed at the open, then fought back to hold above $13, right after a wave of bullish analyst calls. When you see Goldman Sachs, H.C. Wainwright, Oppenheimer, Citizens, and Wells Fargo all raising their targets off the same clinical story, you know sentiment has shifted. Traders watch that kind of consensus re-rating closely, especially with Phase 3 news flow on the horizon.
Still, durability of responses versus other PI3K inhibitors remains an open question, and the wider Q1 loss is a reminder that Relay Therapeutics must keep raising and spending to reach the finish line. That’s why discipline matters. As Tim Sykes likes to tell traders, “Volatility is your best friend and your worst enemy — it rewards prepared traders and punishes lazy ones.” In the same spirit of disciplined trading, as Tim Bohen, lead trainer with StocksToTrade says, “If you’re still guessing at the end of your analysis, it’s probably not a trade worth taking.” RLAY offers plenty of volatility, plus real data and big pharma support. The edge will go to traders who do the homework, respect risk, and treat every spike and dip as a lesson, not a lottery ticket.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.